23rd International AIDS Conference (AIDS 2020), San Francisco and Oakland, United States, 6-10 July 2020

项目摘要 自2018年在阿姆斯特丹举行的第22届国际艾滋病大会以来， 在艾滋病科学领域取得了可喜的进展。预防和治疗的级联很可能是 随着这些进展的完善并进入临床和艾滋病毒项目，未来几年将发生变化。虽然 我们可以说拥有必要的工具来结束这一流行病，艾滋病毒的发病率一直停滞不前，或者在一些国家， 由于一些主要的社会决定因素，包括持续的耻辱感， 歧视、倒退的药物使用政策、贫困、不稳定的住房和交叉的耻辱 包括性别和种族/族裔;以及政治脆弱性和人口流动性。全球会议 它汇集了科学家，实施者，受影响的社区，政府和其他利益相关者， 在这一关键时刻迫切需要。艾滋病2020年也必须是一个关于问责制的会议， 为什么我们未能实现2020年全球和美国新感染率下降的目标， 以及为什么我们继续看到太多的艾滋病死亡和持续的耻辱和歧视。 艾滋病2020将在旧金山弗朗西斯科和奥克兰举行，预计至少有2万名艾滋病毒感染者参加 科学家、临床医生、决策者以及民间社会、社区和私营部门的代表。艾滋病2020 将促进迫切需要的合作，突出特定流行病的轨迹，并侧重于 在不同的政治和社会经济背景下有效应对的模式，供辩论和传播。 选择2020年艾滋病双主办城市的部分原因是，这两个城市在以下方面表现出不平等： 社会经济决定因素，现在面临着艾滋病毒流行病的不同轨迹，与其他 美国国内的环境和全球南北之间的不平等。 艾滋病2020年的具体目标是： 1.介绍艾滋病毒科学在该领域许多相关学科中的最新进展， 特别强调免疫学和病毒学的进展，以帮助开发安全有效的疫苗， 关于推进治愈议程的战略;关于采用新型交付平台的更安全的艾滋病毒疗法;以及 管理合并感染和合并症，特别是随着患者年龄的增长。 2.促进以权利为基础、循证知情、公平供资、适合需要的艾滋病毒方案拟订工作 感染艾滋病毒或面临风险的主要和脆弱社区，包括流离失所者、 与男子、妇女和少女、监狱和其他封闭环境中的人发生性关系， 吸毒者、性工作者、土著居民、变性人、儿童和青年。 3.研究耻辱、社会不公正和健康的社会决定因素对艾滋病毒感染者的影响。 流行病和分析不同的地方流行病，特别是在北美和拉丁美洲，以加强 在获得保健服务和社区社会保障方面进行创新的证据基础。 4.加强政府、捐助者、私营部门和民间社会的承诺， 可持续和资金充足的艾滋病毒应对措施，促进保健覆盖面和获得保健的机会， 全面预防办法，推动普及抗逆转录病毒疗法和预防接触 预防覆盖面，改革禁止性和反生产性药物及其他相关政策。 5.扩大年轻人的声音，强调培养下一代临床医生， 研究人员、教育工作者和倡导者，为青年和 新兴领导人有意义地领导关于科学，研究，政策和计划的讨论 科学计划将新包括六个轨道：轨道A -基础和转化研究;轨道B - 临床研究;轨道C -流行病学和预防科学;轨道D -社会和行为 研究;跟踪电子-实施研究，经济学，系统和协同与其他卫生和 F轨道-政治研究、法律、政策和人权。贯穿各领域的问题将 在全体会议上讨论，也连接科学轨道与社区和领导的观点， 和桥接会议将跨越至少两个轨道，为多学科提供机会， 对话。青年研究人员、基础科学家和相关领域研究人员的参与， 将通过积极征求相关科学意见和提供 具体的财政支持，以及更多的远程访问选项。会议的关键科学将 在艾滋病2020年之后，在区域范围内传播和讨论。会议将利用 在探索使用技术时， 在提供差别化服务的背景下，为预防、治疗和护理提供创新平台。

Project Summary Since the 22nd International AIDS Conference in Amsterdam in 2018, there has been an extraordinary array of promising advances across HIV science. Both the prevention and treatment cascades are likely to be transformed in coming years as these advances are refined and enter the clinic and HIV programs. Although we arguably have the necessary tools to end the epidemic, HIV incidence has been stagnant or, in some places, increasing, due to a number of primarily social determinants, including continued stigma and discrimination, regressive substance use policies, poverty, unstable housing, and intersectional stigmas including gender and race/ethnicity; as well as political fragility and population mobility. A global convening which brings together scientists, implementors, affected communities, governments and other stakeholders is urgently needed at this critical juncture. AIDS 2020 must also be a convening on accountability, to stake stock of why we have failed to achieve 2020 targets of declines in new infections, globally and in the United States, and why we continue to see too many AIDS deaths and persistent stigma and discrimination. AIDS 2020 will be held in San Francisco and Oakland, with an expected attendance of at least 20,000 HIV scientists, clinicians, policy makers, and civil society, community and private sector representatives. AIDS 2020 will facilitate urgently needed collaborations, highlighting the trajectories of specific epidemics and focusing on models of effective responses in different political and socio-economic contexts for debate and dissemination. The dual host cities of AIDS 2020 were chosen in part because these two cities demonstrate inequities in socio-economic determinants and now face different trajectories in their HIV epidemics, paralleling other settings within the United States and echoing inequities between the global North and South. The specific aims of AIDS 2020 are to: 1. Present the latest advances in HIV science across the many relevant disciplines in the field, with particular emphasis on advances in immunology and virology to help develop a safe and effective vaccine, on strategies to further the cure agenda; on safer HIV therapies with novel delivery platforms; and on managing co-infections and co-morbidities, especially as patients age. 2. Promote rights-based, evidence-informed, equitably funded HIV programming tailored to the needs of key and vulnerable communities living with HIV or at risk, including displaced populations, men who have sex with men, women and adolescent girls, people in prisons and other closed settings, people who use drugs, sex workers, indigenous populations, transgender people, children and youth. 3. Examine the impact of stigma, social injustice and social determinants of health on the HIV epidemic and analyze different local epidemics, particularly within North and Latin America, to strengthen the evidence base for innovation in access to healthcare services and social protection for communities. 4. Strengthen commitment from governments, donors, the private sector and civil society for an inclusive, sustainable and adequately financed HIV response that promotes health coverage and access, scales up comprehensive prevention approaches, advances universal antiretroviral therapy and pre-exposure prophylaxis coverage, and reforms prohibitive and counterproductive drug and other relevant policies. 5. Amplify the voices of young people and emphasize training of the next generation of clinicians, researchers, educators, and advocates by providing an innovative and inclusive platform for youth and emerging leaders to meaningfully lead discussions on science, research, policy and programs The scientific program will newly consist of six tracks: Track A - Basic and Translational Research; Track B - Clinical Research; Track C - Epidemiology and Prevention Science; Track D - Social and Behavioural Research; Track E - Implementation Research, Economics, Systems and Synergies with other Health and Development Sectors; and Track F - Political research, law, policy and human rights. Cross-cutting aspects will be covered in plenary talks that also connect the scientific tracks with community and leadership perspectives, and bridging sessions will cut across at least two of the tracks to provide opportunities for multi-disciplinary dialogues. The participation of young researchers, basic scientists and researchers in related fields such as non-communicable diseases will be strengthened by active solicitation of relevant science and the provision of specific financial support, in addition to increased remote-access options. Key science from the conference will be disseminated and discussed in regional contexts following AIDS 2020. The conference will take advantage of its proximity to leading technology companies in the Bay Area when exploring the use of technologies in innovative delivery platforms for prevention, treatment and care in the context of differentiated service delivery.